News

July 29, 2016
Second Quarter 2016 Financial Results
Double-digit revenue and adjusted EPS growth for the 6th consecutive quarter

Our robust portfolio drove double-digit revenue and adjusted earnings growth in Q2. Our strategic acquisition of Stemcentrx, in addition to regulatory approvals further expanded our presence in oncology and neuroscience. Read the full press release.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?